Journal Watch · Frontiers in Immunology · 2026

Pulmonary injury in inflammatory bowel disease: intestinal barrier disruption, gut-lung axis remodeling, and treatment-related lung toxicity.

In the future, emphasis should be placed on establishing a stratified diagnostic framework for distinguishing pulmonary involvement intrinsic to the disease, infection, and drug-induced pulmonary injury, and on evaluating precision intervention strategies targeting microbial function, metabolite supplementation, and barrier repair to advance the translational application of mechanistic research on IBD-associated pulmonary injury into clinical practice.

Mu Z, Zhou R, Hao W et al.Frontiers in Immunology3 min readPharma relevance 40/100

DOI: 10.3389/fimmu.2026.1883855PMID: 42524083Study type: cohort / observational clinical study

TL;DR

In the future, emphasis should be placed on establishing a stratified diagnostic framework for distinguishing pulmonary involvement intrinsic to the disease, infection, and drug-induced pulmonary injury, and on evaluating precision intervention strategies targeting microbial function, metabolite supplementation, and barrier repair to advance the translational application of mechanistic research on IBD-associated pulmonary injury into clinical practice.

Key findings

  • Existing studies suggest that SCFAs, tryptophan metabolites, immune cell homing, and alterations in the local pulmonary microbiota may represent key regulatory nodes in IBD-associated pulmonary injury; however, prospective studies integrating intestinal inflammatory activity, circulating biomarkers, pulmonary phenotypes, and drug exposure are still lacking.
  • In the future, emphasis should be placed on establishing a stratified diagnostic framework for distinguishing pulmonary involvement intrinsic to the disease, infection, and drug-induced pulmonary injury, and on evaluating precision intervention strategies targeting microbial function, metabolite supplementation, and barrier repair to advance the translational application of mechanistic research on IBD-associated pulmonary injury into clinical practice.

What they did

Growing evidence indicates that IBD-associated pulmonary injury is not an isolated pulmonary event but rather a cross-organ pathological process jointly driven by disruption of the intestinal mucosal barrier, dysbiosis, and aberrant microbial metabolites, systemic inflammation, and abnormal immune cell trafficking. This article provides a comprehensive review of current basic and clinical research evidence regarding intestinal barrier dysfunction, bidirectional gut-lung axis regulation, immune remodeling mediated by microbial metabolites, such as short-chain fatty acids (SCFAs), and the mechanisms and differential diagnosis of drug-induced pulmonary injury in IBD treatment.

Full abstract (original)

Background: Inflammatory bowel disease (IBD)-associated pulmonary injury is one of the frequently underestimated extraintestinal manifestations in clinical practice. It can present as subclinical pulmonary function abnormalities, radiographic changes, or overt inflammatory pulmonary diseases and often overlaps with infection- and treatment-related pulmonary toxicity, complicating early recognition and differential diagnosis.

What they did: Growing evidence indicates that IBD-associated pulmonary injury is not an isolated pulmonary event but rather a cross-organ pathological process jointly driven by disruption of the intestinal mucosal barrier, dysbiosis, and aberrant microbial metabolites, systemic inflammation, and abnormal immune cell trafficking. This article provides a comprehensive review of current basic and clinical research evidence regarding intestinal barrier dysfunction, bidirectional gut-lung axis regulation, immune remodeling mediated by microbial metabolites, such as short-chain fatty acids (SCFAs), and the mechanisms and differential diagnosis of drug-induced pulmonary injury in IBD treatment.

Results & conclusions: Existing studies suggest that SCFAs, tryptophan metabolites, immune cell homing, and alterations in the local pulmonary microbiota may represent key regulatory nodes in IBD-associated pulmonary injury; however, prospective studies integrating intestinal inflammatory activity, circulating biomarkers, pulmonary phenotypes, and drug exposure are still lacking. In the future, emphasis should be placed on establishing a stratified diagnostic framework for distinguishing pulmonary involvement intrinsic to the disease, infection, and drug-induced pulmonary injury, and on evaluating precision intervention strategies targeting microbial function, metabolite supplementation, and barrier repair to advance the translational application of mechanistic research on IBD-associated pulmonary injury into clinical practice.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1883855 · PubMed 42524083.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

In the future, emphasis should be placed on establishing a stratified diagnostic framework for distinguishing pulmonary involvement intrinsic to the disease, infection, and drug-induced pulmonary injury, and on evaluating precision intervention strategies targeting microbial function, metabolite supplementation, and barrier repair to advance the translational application of mechanistic research on IBD-associated pulmonary injury into clinical practice.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Growing evidence indicates that IBD-associated pulmonary injury is not an isolated pulmonary event but rather a cross-organ pathological process jointly driven by disruption of the intestinal mucosal barrier, dysbiosis, and aberrant microbial metabolites, systemic inflammation, and abnormal immune cell trafficking.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1883855. PubMed ID: 42524083. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Mu Z, Zhou R, Hao W et al.. Pulmonary injury in inflammatory bowel disease: intestinal barrier disruption, gut-lung axis remodeling, and treatment-related lung toxicity.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1883855.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/pulmonary-injury-in-inflammatory-bowel-disease-intestinal-barrier-disrup-883855/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides